Skip to main content

Menopausal Hormone Therapy (MHT) discontinuation and shortages March 2025

Australia 

Patch Shortages

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia. Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.

Oestradiol patches

 

Availability and expected supply due

Alternative supply under Section 19A

Dose

Estradot

Estraderm

Estramon

Estradiol Transdermal System

25 mcg

Limited - 31 Dec 2025

Limited - 30th June 2025

Available

 

37.5 mcg

Unavailable - 30th Jun 2025

 

Available

Available

50 mcg

Unavailable - 31st Dec 2025

Limited - 30th June 2025

Available

Unavailable

75 mcg

Limited - 31st Dec 2025

Limited - 30th June 2025

Available

Unavailable

100 mcg

Unavailable - 31 Dec 2025

Limited - 7th April 2025

Available

Available

Combined patches

Dose

Estalis Sequi

Estalis Conti

50/140

Limited – 30th June 2025

Unavailable – 30th June 2025

50/250

Limited – 30th June 2025

Limited – 30th June 2025

All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.

The AMS Guide to MHT Doses (Australia only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

New Zealand

As at 11 December 2024, patch availability is provided below.

Dose

Estradot

Viatris

Estraderm MX

25mcg

Limited

Available 

Available

50mcg

Limited

Available

 

75mcg

Limited

Available

 

100mcg

Limited

Available

 

More information can be found here  

Read more …Menopausal Hormone Therapy (MHT) discontinuation and shortages March 2025

Menopausal Hormone Therapy (MHT) discontinuation and shortages February 2025

Australia 

Patch Shortages

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia. Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.

Oestradiol patches

 

Availability and expected supply due

Alternative supply under Section 19A

Dose

Estradot

Estraderm

Estramon

Estradiol Transdermal System

25 mcg

Limited - 31 Dec 2025

Limited - 30th June 2025

Available

 

37.5 mcg

Unavailable - 30th Jun 2025

 

Available

Available

50 mcg

Unavailable - 31st Dec 2025

Limited - 30th June 2025

Available

Unavailable

75 mcg

Limited - 31st Dec 2025

Limited - 30th June 2025

Available

Unavailable

100 mcg

Unavailable - 31 Dec 2025

Limited - 7th April 2025

Available

Available

Combined patches

Dose

Estalis Sequi

Estalis Conti

50/140

Limited – 30th June 2025

Unavailable – 30th June 2025

50/250

Limited – 30th June 2025

Limited – 30th June 2025

All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.

The AMS Guide to MHT Doses (Australia only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

New Zealand

As at 11 December 2024, patch availability is provided below.

Dose

Estradot

Viatris

Estraderm MX

25mcg

Limited

Available 

Available

50mcg

Limited

Available

 

75mcg

Limited

Available

 

100mcg

Limited

Available

 

More information can be found here  

Read more …Menopausal Hormone Therapy (MHT) discontinuation and shortages February 2025

New PBS additions to ease menopausal hormone therapy shortage

19 February 2025

Menopause therapy subsidies break 20-year drought1

Australian women suffering from the debilitating symptoms of menopause will have access to the first new kind of menopausal hormone therapy to be subsidised by the Federal Government in more than two decades.

From 1 March, three menopausal hormone therapies – Estrogel® Pro (estradiol / progesterone), Estrogel® (estradiol) and Prometrium® (progesterone) – will become available through the Pharmaceutical Benefits Scheme (PBS) to help alleviate menopausal symptoms women who have reached menopause.1

Currently, more than 100,000 Australian women are paying privately for these medicines.2 Without the subsidy, women could pay around $650 per year for modern menopause therapy, depending on individual pharmacy pricing. Under the PBS, eligible patients will pay just $7.70 (pension and concession card holders) or up to $31.60 (general patients) each month for Estrogel Pro, Estrogel or Prometrium.3

The new subsidies follow:

  • The 2024 Parliamentary Inquiry into Menopause and Perimenopause recommendation that newer forms of menopause therapies be subsidised through the PBS to bolster supply and “ensure appropriate access and lowered costs for all women who need it”;4
  • Therapeutic Goods Administration advice that supply shortages of currently PBS-listed menopausal treatment options will persist throughout 2025, and that prescribing those therapies for new patients should be limited to “help preserve available supply for existing patients”.5

The funding move is being welcomed by women’s health experts, including Dr Sonia Davison, Endocrinology Lead at the Jeans Hailes Clinic, who said: “This is wonderful news that will make a meaningful difference to the lives of countless Australian women”.

“This decision acknowledges the impact of menopause on women's lives and ensures they have access to modern treatment without a sizeable cost burden,” she said.

“For far too long, menopausal women have had their experiences dismissed and faced barriers to accessing affordable treatment options.”

One in four women experience severe or prolonged menopausal symptoms that affect their quality of life and may require treatment.6

“While menopause is a normal and natural part of ageing, it’s important that women realise that the symptoms affecting their quality of life are very treatable,” Dr Davison said. “They should not suffer in silence”.

“Too often, menopause is dismissed as simply hot flushes or moodiness. The reality is that, for some women, the dramatic drop in hormone levels can cause a raft of symptoms that may last for years.” 

Menopause describes the natural stage of a woman's life when her menstrual period permanently stops. It is caused by a drop in reproductive hormones – especially estrogen – that can begin many years earlier, during a phase known as perimenopause.7

Menopause hormone therapies such as Estrogel Pro, Estrogel and Prometrium help to replace the hormones lost by the body, to bring them back up to premenopausal levels, thereby reducing symptoms that may interfere with daily life.8,9

Menopause, which typically sets in around the age of 51,10 can lead to hot flushes, night sweats, sleep deprivation, muscle and joint pain, mood changes and increased irritability, brain fog, and decreased concentration and executive function. Symptoms typically last for around seven years.11

“There’s a reason that menopause is known as ‘the change of life’. It really can be life-altering and can impact almost every aspect of a woman’s life – from her sense of self, physical and mental wellbeing, to relationships and even her ability to work,” said Dr Davison.

Research shows that more than two-thirds (69 per cent) of Australian women aged 45-64 who had reached menopause have been troubled by menopausal symptoms. For more than 40 per cent of these women, the symptoms made daily activities difficult.12

“Sadly, for some women, the physical and psychological symptoms of menopause can be debilitating and completely overwhelming,” said Dr Davison.

“In 2025, menopause should not be overlooked or taboo. We must all understand that while menopause is normal, the discomfort, poor health and reduced quality of life often caused by menopause are not unavoidable consequences of ageing.”

Read more …New PBS additions to ease menopausal hormone therapy shortage

SANDRENA PBS 0.5G listing NOV 2024

19 February 2025

SANDRENA® estradiol gel 0.1% 0.5g dose joined the SANDRENA 1.0g dose on the PBS from the 1st November 2024. The 0.5g sachet allows for more accurate dose modification across the three TGA registered doses of 0.5mg, 1.0mg and 1.5mg Sandrena estradiol 0.1% gel1

Women with a healthcare card pay $7.70 monthly for the medium dose of 1.0g sachet and the lower dose of 0.5g sachet. Non-concessional card holders continue to pay less than $20 per month for the 1.0g sachet and less than $15 per box for the 0.5g sachet. SANDRENA allows the flexibility to combine with the preferred form of progestogen in non-hysterectomised women¹.

Supply of some Australian-registered HRT patch products will remain very limited in 20252. The TGA asks prescribers to …”please consider these shortages when initiating new patients on HRT transdermal patches. Limiting initiations in this shortage period will help preserve available supply for existing patients”2..

From 1st March 2025 all Estradiol Transdermal gels will be PBS listed.  

Further information on Sandrena is available in the Consumer Medicines Guide.

Read more …SANDRENA PBS 0.5G listing NOV 2024

Menopausal Hormone Therapy (MHT) discontinuation and shortages January 2025

Australia 

Patch Shortages

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia. Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.

Oestradiol patches

 

Availability and expected supply due

Alternative supply under Section 19A

Dose

Estradot

Estraderm

Estramon

Estradiol Transdermal System

25 mcg

Unavailable - 31 Dec 2025

Limited - 30th June 2025

Available

 

37.5 mcg

Unavailable - 30 Jun 2025

 

Available

Available

50 mcg

Unavailable - 31 Dec 2025

Limited - 30th June 2025

Available

Unavailable

75 mcg

Unavailable - 31 Dec 2025

Limited - 7 Feb 2025

Available

Unavailable

100 mcg

Unavailable - 31 Dec 2025

Limited - 7 April 2025

Available

Available

Combined patches

Dose

Estalis Sequi

Estalis Conti

50/140

Limited – 30 June 2025

Limited – 30 June 2025

50/250

Limited – 30 June 2025

Limited – 30 June 2025

All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.

The AMS Guide to MHT Doses (Australia only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

New Zealand

As at 11 December 2024, patch availability is provided below.

Dose

Estradot

Viatris

Estraderm MX

25mcg

Limited

Available 

Available

50mcg

Limited

Available

 

75mcg

Limited

Available

 

100mcg

Limited

Available

 

More information can be found here  

Read more …Menopausal Hormone Therapy (MHT) discontinuation and shortages January 2025

Menopausal Hormone Therapy (MHT) discontinuation and shortages December 2024

Australia 

Patch Shortages

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia. Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.

Oestradiol patches

 

Expected supply due

Alternative supply under Section 19A

Dose

Estradot

Estraderm

Estramon

Estradiol Transdermal System

25 mcg

31 Dec 2025

16 Dec 2024

Available

 

37.5 mcg

30 Jun 2025

 

Available

Available

50 mcg

31 Dec 2025

16 Dec 2024

Available

Unavailable

75 mcg

31 Dec 2025

16 Dec 2024

Available

Unavailable

100 mcg

31 Dec 2025

16 Dec 2024

Available

Available

Combined patches

Dose

Estalis Sequi

Estalis Conti

50/140

Limited

Limited

50/250

Limited

Limited

All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.

The AMS Guide to MHT Doses (Australia only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

New Zealand

As at 11 December 2024, patch availability is provided below.

Dose

Estradot

Viatris

Estraderm MX

25mcg

Low

Available 

Available

50mcg

Low

Available

 

75mcg

Low

Available

 

100mcg

Low

Available

 

More information can be found here  

Read more …Menopausal Hormone Therapy (MHT) discontinuation and shortages December 2024

Menopausal Hormone Therapy (MHT) discontinuation and shortages November 2024

Australia 

Patch Shortages

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia. Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.

Oestradiol patches

 

Expected supply due

Alternative supply under Section 19A

Dose

Estradot

Estraderm

Estramon

Estradiol Transdermal System

25 mcg

31 Dec 2024

5 Dec 2024

Available

 

37.5 mcg

30 Jun 2025

 

Available

Available

50 mcg

31 Jan 2025

5 Dec 2024

Available

Unavailable

75 mcg

31 Jan 2025

5 Dec 2024

Available

Unavailable

100 mcg

31 Dec 2024

5 Dec 2024

Available

Available

Combined patches

Dose

Estalis Sequi

Estalis Conti

50/140

Available

Available

50/250

Available

Available

All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.

The AMS Guide to MHT Doses (Australia only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

New Zealand

As at 21 November 2024, patch availability is provided below.

Dose

Estradot

Viatris

Estraderm MX

25mcg

Low

Available 

Available

50mcg

Low

Available

 

75mcg

Low

Available

 

100mcg

Low

Available

 

More information can be found here  

Read more …Menopausal Hormone Therapy (MHT) discontinuation and shortages November 2024

Menopausal Hormone Therapy (MHT) discontinuation and shortages October 2024

Australia

Patch Shortages

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia. Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.

Oestradiol patches

 

Expected supply due

Alternative supply under Section 19A

Dose

Estradot

Estraderm

Estramon

Estradiol Transdermal System

25 mcg

20 Jan 2025

24 Nov 2024

Available

 

37.5 mcg

20 Jan 2025

 

Available

20 Jan 2025

50 mcg

20 Jan 2025

24 Nov 2024

Available

20 Jan 2025

75 mcg

20 Jan 2025

11 Nov 2024

Available

20 Jan 2025

100 mcg

20 Jan 2025

25 Nov 2024

Available

20 Jan 2025

Combined patches

Dose

Estalis Sequi

Estalis Conti

50/140

Available

Available

50/250

Available

28th Nov 2024

All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.

The AMS Guide to MHT Doses (Australia only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

New Zealand

As at 28th October 2024, patch availability is provided below.

Dose

Estradot

Viatris

Estraderm MX

25mcg

Low

Available

Available

50mcg

Low

Available

 

75mcg

Low

Available

 

100mcg

Low

Available

 

More information can be found here  

Read more …Menopausal Hormone Therapy (MHT) discontinuation and shortages October 2024

Menopausal Hormone Therapy (MHT) discontinuation and shortages September 2024

Australia 

Patch Shortages

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia. Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.

Oestradiol patches

 

Expected supply due

Alternative supply under Section 19A

Dose

Estradot

Estraderm

Estramon

Estradiol Transdermal System

25 mcg

20 Jan 2025

Available

Available

 

37.5 mcg

16 Dec 2024

 

Available

Available

50 mcg

20 Jan 2025

Available

Available

 Available

75 mcg

21 Oct 2024

11 Nov 2024

Available

Available

100 mcg

28 Oct 2024

Available

Available

Available

Combined patches

Dose

Estalis Sequi

Estalis Conti

50/140

Available

20 Sep 2024

50/250

Available

Available

All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.

The AMS Guide to MHT Doses (Australia only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

New Zealand

As at 17th September 2024, patch availability is provided below.

Dose

Estradot

Viatris

Estraderm MX

25mcg

Low

Available 

Available

50mcg

Low

Available

 

75mcg

Low

Available

 

100mcg

Low

Available

 

More information can be found here  

Read more …Menopausal Hormone Therapy (MHT) discontinuation and shortages September 2024

Menopausal Hormone Therapy (MHT) patch shortages August 2024

Australia 

Patch Shortages

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia. Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.

Oestradiol patches

 

Expected supply due

Alternative supply under Section 19A

Dose

Estradot

Estraderm

Estramon

Estradiol Transdermal System

25 mcg

20 Jan 2025

Low avaiability

Available

 

37.5 mcg

16 Dec 2024

 

Available

Available

50 mcg

20 Jan 2025

Available

Available

 Available

75 mcg

16 Sep 2024

30 Sep 2024

Available

Available

100 mcg

18 Oct 2024

Available

Available

Available

Combined patches

Dose

Estalis Sequi

Estalis Conti

50/140

17 June 2024

8 Jun 2024

50/250

15 Jul 2024

3 Aug 2024

All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.

The AMS Guide to MHT Doses (Australia only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

Read more …Menopausal Hormone Therapy (MHT) patch shortages August 2024